AsthmaCHI3L1NCT01348932
The Relationship Between Single Nucleotide Polymorphisms of Chitinase 3-like 1 Gene,YKL-40 Serum Levels and Adult Asthma
An observational study of Asthma, run by China Medical University Hospital at 1 site in Taiwan.
Trial summary
The objective of this study was to investigate the relationship between single nucleotide polymorphism of chitinase 3-like 1 and human asthma. Read more about this study
- Who is it for?
- Ages 20 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Asthma
- How many people
- 1 participants
- Where
- 1 siteTaiwan
- Study dates
- May 2011to Dec 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Taiwan
Who may be able to join
- ages 20 to 60 years
- asthma patients
- atopy patients
- control (non-asthma and non-atopy)
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
China Medical University Hospital
2 Yuh-Der Road, Taichung, 40447
Chen Chia Hung, doctor, 0975680802, hsnu758@gmail.com
About this study
The objective of this study was to investigate the relationship between single nucleotide polymorphism of chitinase 3-like 1 and human asthma.
Read the detailed description
Chitinase 3-like 1 (CHI3L1) is a member of human chitinases family. According to previous studies in literatures, increased expression of CHI3L1 has been proven to be correlated with the presence of different diseases, including cancers, autoimmune diseases, and chronic inflammatory conditions. Elevated serum levels of YKL-40 are associated with increased disease severity, poorer prognosis and shorter survival for many other diseases. When monitored over time, increases in serum YKL-40 parallel with disease progression. It can serve as an measurable marker of changes in disease status.
There were indicated that chitinase 3-like 1 might be associated with some clinical diseases. The C-allele of the -131 C→G (rs4950928) polymorphism of CHI3L1 has been shown to associate with bronchial hyperresponsiveness and reduced lung function. It is suggesting that variations in CHI3L1 may influence risk of asthma.
The objective of this study was to investigate the relationship between single nucleotide polymorphism of chitinase 3-like 1 and human asthma. The association between CHI3L1 SNPs and the continuous outcomes were examined by real time PCR and gene sequencing analysis.
In Korean reports there was no significant associations between CHI3L1 SNPs and asthma were observed. On the other hand, there were association between CHI3L1 and asthma observed in the majority of Caucasian populations. However, similar research has not been conducted in Taiwan. In contrast to preliminary studies, the investigators predict the rs4950928 G allele, and not the C allele, was found to be associated with asthma. The g.-247C/T polymorphism in the CHI3L1 promoter region is associated with the risk of atopy.
- Conditions
- Asthma
- Keywords
- asthma, Chitinase 3-like 1 (CHI3L1), YKL-40, single nucleotide polymorphism(SNP), Real time PCR, gene
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Asthma | The relationship between single nucleotide polymorphisms of chitinase 3-like 1 gene, YKL-40 serum levels and adult asthma |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2011 (estimated)
- Study startMay 2011
- Primary completionJun 2011 (estimated)
- Study completionDec 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- More trials run by China Medical University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 1 participants (estimated)
Sponsor and investigators
- Lead sponsor
- China Medical University Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Chen Chia Hung, doctor, Study director, Partners
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01348932
- Sponsor's protocol ID
- DMR100-IRB-008
- Acronym
- CHI3L1
- Status last verified
- May 2011
- First submitted
- 4 May 2011
- Last updated
- 6 May 2011
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Relationship Between Single Nucleotide Polymorphisms of Chitinase 3-like 1 Gene,YKL-40 Serum Levels and Adult Asthma
- ClinicalTrials.gov ID
- NCT01348932
- Acronym / sponsor ID
- CHI3L1 / DMR100-IRB-008
- Conditions
- Asthma
- Keywords
- asthma, Chitinase 3-like 1 (CHI3L1), YKL-40, single nucleotide polymorphism(SNP), Real time PCR, gene
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1 participants (estimated)
- Lead sponsor
- China Medical University HospitalUniversity, hospital or other
- Study start
- May 2011
- Primary completion
- Jun 2011 (estimated)
- Study completion
- Dec 2013 (estimated)
- First posted
- 6 May 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study was to investigate the relationship between single nucleotide polymorphism of chitinase 3-like 1 and human asthma.
Detailed description
Chitinase 3-like 1 (CHI3L1) is a member of human chitinases family. According to previous studies in literatures, increased expression of CHI3L1 has been proven to be correlated with the presence of different diseases, including cancers, autoimmune diseases, and chronic inflammatory conditions. Elevated serum levels of YKL-40 are associated with increased disease severity, poorer prognosis and shorter survival for many other diseases. When monitored over time, increases in serum YKL-40 parallel with disease progression. It can serve as an measurable marker of changes in disease status.
There were indicated that chitinase 3-like 1 might be associated with some clinical diseases. The C-allele of the -131 C→G (rs4950928) polymorphism of CHI3L1 has been shown to associate with bronchial hyperresponsiveness and reduced lung function. It is suggesting that variations in CHI3L1 may influence risk of asthma.
The objective of this study was to investigate the relationship between single nucleotide polymorphism of chitinase 3-like 1 and human asthma. The association between CHI3L1 SNPs and the continuous outcomes were examined by real time PCR and gene sequencing analysis.
In Korean reports there was no significant associations between CHI3L1 SNPs and asthma were observed. On the other hand, there were association between CHI3L1 and asthma observed in the majority of Caucasian populations. However, similar research has not been conducted in Taiwan. In contrast to preliminary studies, the investigators predict the rs4950928 G allele, and not the C allele, was found to be associated with asthma. The g.-247C/T polymorphism in the CHI3L1 promoter region is associated with the risk of atopy.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Asthma | – | –The relationship between single nucleotide polymorphisms of chitinase 3-like 1 gene, YKL-40 serum levels and adult asthma |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Taiwan
Key inclusion criteria (4 listed)
- ages 20 to 60 years
- asthma patients
- atopy patients
- control (non-asthma and non-atopy)
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2011.
Related trials for Asthma
RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma
Asthma
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
RecruitingPhase 2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Asthma
Active, not recruitingPhase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chen Chia Hung, doctor study director
Partners
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Asthma, run by China Medical University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 May 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chen Chia Hung, doctor (0975680802, hsnu758@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2011.